News | February 11, 2015

ASTRO Applauds Medicare’s Final Decision to Cover Annual, Low-Dose CT Screening for High-Risk Lung Cancer Patients

Decision follows USPSTF's recommendation that LDCT is a Grade B screening

Ct systems, lung cancer, radiation therapy, CMS, ASTRO

Image courtesy of Toshiba

February 11, 2015 — The American Society for Radiation Oncology (ASTRO) commends the February 5, 2015, decision by the Centers for Medicare and Medicaid Services (CMS) to provide coverage for annual lung cancer screening via low-dose CT screening for those at highest-risk for lung cancer.

The final Decision Memo for Screening for Lung Cancer with Low Dose Computed Tomography (LDCT) details that there is sufficient evidence to warrant annual lung cancer screening for patients most at-risk for developing lung cancer. The memo outlines the patient criteria for eligibility as follows: aged 55 to 77; showing no signs or symptoms of lung disease; a smoking history of at least 30 pack-years (one pack-year = smoking one pack per day for one year; one pack = 20 cigarettes) and a current smoker or someone who has quit smoking within the last 15 years.

ASTRO Chair Bruce G. Haffty, M.D., FASTRO remarks that, “This year in the United States, it is estimated that nearly 230,000 men and women will be diagnosed with lung cancer, and that there will be more than 160,000 deaths from lung cancer, more deaths than from breast, colon and prostate cancers combined. This highly effective, annual screening is a critical and powerful tool that will enable us to diagnose patients earlier when treatments are most effective, and it will fortify our efforts to battle this destructive disease.”

In addition to detailing the patient health status for annual screening, the final decision also enumerates specific facility criteria and requirements, and care steps prior to and following screening. Two valuable care steps include 1) a shared-decision making/smoking cessation counseling session between the physician and patient prior to the first screening and 2) access to smoking cessation sessions available to current smokers – vital services that encourage current smokers to stop smoking, which directly impacts their treatment outcome. Distinct screening guidelines are also provided: administer CT dose index volume of 3 mGy or less for standard-sized patients (approximately 155 lbs.) with appropriate reductions for smaller patients and increases for larger patients; utilize a standardized lung nodule identification, classification and reporting system and collection and submission of patient data to a CMS-approved registry for each LDCT screening test.

CMS’s decision follows the United States Preventive Task Force’s (USPSTF’s) December 2013 recommendation that LDCT is a Grade B screening, and which reviewed the results of four randomized clinical trials, including the National Cancer Institute’s National Lung Screening Trial, which included more than 50,000 asymptomatic adults aged 55 to 75 who had at least a 30 pack-year history and found a 16 percent reduction in lung cancer mortality for those who received annual screening and thus, earlier treatment.

For more information: www.astro.org

 

Related Content

BrainLAB Announces FDA Clearance For Two New Indication-Specific Radiosurgery Software Applications
Technology | Treatment Planning | September 21, 2017
Brainlab announced that it has received U.S. Food and Drug Administration (FDA) clearance for Elements Spine SRS and...
Accuray Showcases CyberKnife and Radixact Systems at ASTRO 2017
News | Radiation Therapy | September 21, 2017
Accuray Inc. announced that data and first-hand experience with its advanced CyberKnife and Radixact Systems will be...
RayCare Oncology Information System Being Shown at ASTRO 2017
News | Radiation Therapy | September 20, 2017
RaySearch will be exhibiting its next-generation oncology information system (OIS) RayCare, among other highlights, at...
ProCure Proton Therapy Center New Jersey Celebrates Five-Year Cancer-Free Milestone for Prostate Cancer Patients
News | Proton Therapy | September 20, 2017
ProCure Proton Therapy Center in Somerset, N.J., recently celebrated the five-year cancer-free milestone for the first...
Varian to Showcase Latest Radiation Therapy Technologies and Software at ASTRO 2017
News | Radiation Therapy | September 19, 2017
Varian Medical Systems announced it will be demonstrating its new Halcyon platform and HyperArc high-definition...
Elekta to Highlight MOSAIQ Oncology Analytics at ASTRO Annual Meeting
News | Radiation Therapy | September 19, 2017
September 19, 2017 — Elekta will highlight its Mosaiq Oncology...
Toshiba Highlights Latest CT Advancements at RSNA 2017
News | Computed Tomography (CT) | September 18, 2017
Toshiba Medical announced that it will display several new enhancements to its existing computed tomography (CT)...
Hitachi Supria True64 CT Receives FDA Clearance
Technology | Computed Tomography (CT) | September 15, 2017
September 15, 2017 — Hitachi Healthcare Americas Inc. announced it has attained U.S.
Double Targeting Ligands to Identify and Treat Prostate Cancer

The mice were imaged with small-animal PET/CT using 124I-RPS-027 (7.4 MBq [200 μCi]). Credit: JM Kelly et al., Department of Radiology, Weill Cornell Medicine, New York, NY

News | Prostate Cancer | September 14, 2017
Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while...
Clinical Trials and Cutting-Edge Radiation Oncology Research to Be Featured at ASTRO 2017
News | Radiation Therapy | September 14, 2017
The program for the 2017 Annual Meeting of the American Society for Radiation Oncology (ASTRO), Sept. 24-27 in San...
Overlay Init